CareLit · DOI-Nachweis · Geburtshilfe und Frauenheilkunde
Second interims analysis of the ARA Plus study – Breast Cancer (BC) adjuvant chemotherapy (CT) with and without darbepoetin alfa (Aranesp®) – Analysis serious adverse events
DOI 10.1055/s-2008-1075796
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Warm, C Oberhoff, K Ziegler, T Reimer, S Mohrmann, C Schumacher, O Gluz, F Werner, I Zuna, U Nitz
ZeitschriftGeburtshilfe und Frauenheilkunde
Ausgabe04/2008
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Adjuvant chemotherapy improves survival in node positive breast cancer. TAC is one of the most effective regimens, but it is associated with higher frequency of anemia and chemotherapy-induced neutropenia (CIN). The erythropoiesis stimulating factor (ESF) support of chemotherapy, its complications and survival effect remain unclear. Erythropoetins do prevent chemotherapy-associated anemia (CAA) and subsequent fatigu…
Zitieren
Zitierempfehlung
M Warm, C Oberhoff, K Ziegler, T Reimer, S Mohrmann, C Schumacher, O Gluz, F Werner, I Zuna, U Nitz (2008) Second interims analysis of the ARA Plus study – Breast Cancer (BC) adjuvant chemotherapy (CT) with and without darbepoetin alfa (Aranesp®) – Analysis serious adverse events. Geburtshilfe und Frauenheilkunde (04). https://doi.org/10.1055/s-2008-1075796
Mit CareLit weiterarbeiten